NCT02600949 — M.D. Anderson Cancer Center cancer vaccine trial
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Registry record
| Registry ID | NCT02600949 ↗ |
|---|---|
| Lead sponsor | M.D. Anderson Cancer Center |
| Collaborators | National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Enrolling By Invitation |
| Indication | Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 |
| Enrollment | 300 participants (target) |
| Start date | 2016-05-11 |
| Primary completion | 2027-05-31 (est.) |
| Last registry update | 17 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT02600949), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT02600949?
NCT02600949 (Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by M.D. Anderson Cancer Center.
Is NCT02600949 recruiting?
As of the 2026-06-17 registry update, NCT02600949 is listed as "Enrolling By Invitation". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT02600949?
The lead sponsor is M.D. Anderson Cancer Center. Collaborators: National Cancer Institute (NCI).
What condition does NCT02600949 study?
The registered conditions are Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7. Primary completion is listed as 2027-05-31 (estimated).
Are results available for NCT02600949?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT02600949.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.